Pioglitazone , ≥98% , 111025-46-8

CAS NO.：111025-46-8

Empirical Formula: C19H20N2O3S

Molecular Weight: 356.44

MDL number: MFCD00865504

EINECS: 601-029-7

PRODUCT Properties

• Melting point: 183-184 C
• Boiling point: 575.4±45.0 °C(Predicted)
• Density: 1.260±0.06 g/cm3(Predicted)
• storage temp.: under inert gas (nitrogen or Argon) at 2-8°C
• solubility: DMSO (Slightly, Heated)
• pka: 6.35±0.50(Predicted)
• form: White to off-white solid.
• color: White to Off-White
• InChI: InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
• InChIKey: HYAFETHFCAUJAY-UHFFFAOYSA-N
• SMILES: S1C(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C(=O)NC1=O
• IARC: 2A (Vol. 108) 2016

Description and Uses

Pioglitazone is an agonist of the peroxisome proliferator-activated receptor γ (PPARγ; EC₅₀ = ~500-600 nM for both human and murine PPARγ). It is selective for PPARγ over PPARα, exhibiting low level activation of PPARα at 1 μM and 5.4-fold activation at a concentration of 10 μM. Pioglitazone inhibits pyruvate oxidation and glucose production in hepatocytes when used at a concentration of 10 μM. In vivo, pioglitazone (0.3-3 mg/kg per day) reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in a dose-dependent manner in male Wistar fatty rats. It reduces the number of lesions in a transgenic rat adenocarcinoma of prostate (TRAP) model. Pioglitazone (2.5 mg/kg) also decreases production of neuroinflammatory cytokines and reduces immobility in the forced swim and tail suspension tests in a mouse model of chronic mild stress, indicating antidepressant-like activity that can be reversed by the PPARγ antagonist GW9662 .

antihyperlipidemic, HMGCoA reductase inhibitor

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Warning
• Hazard statements: H302-H312-H332-H351-H361
• Precautionary statements: P280
• Hazard Codes: F,C
• Risk Statements: 11-34
• Safety Statements: 16-26-36/37/39-45
• Hazardous Substances Data: 111025-46-8(Hazardous Substances Data)